| Description | Glycogen phosphorylase-IN-1 is a selective and potent inhibitor of human hepatic glycogen phosphorylase (hlGPa) with inhibitory effects on hlGPa activity and on hepatocyte glycogen-derived glucose production, and can be used in the study of type 2 diabetes mellitus and canine lupus. |
| In vivo | 在 Wistar 大鼠的胰高血糖素刺激高血糖模型中，Glycogen phosphorylase-IN-1（5 mg/kg；静脉注射，单剂量）能够降低血糖水平[1]。 |
| molecular weight | 412.78 |
| Molecular formula | C17H15ClF2N4O4 |
| CAS | 648926-15-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMF: 2 mg/mL (4.85 mM), Sonication is recommended. DMSO: 2 mg/mL (4.85 mM), Sonication is recommended. |
| References | 1. Klabunde T, et al., Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. J Med Chem. 2005 Oct 6;48(20):6178-93. |